2026年單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物全球市場報告

近年來，用於單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）的放射性藥物市場規模顯著擴大。預計該市場將從2025年的65.3億美元成長到2026年的70.4億美元，複合年成長率（CAGR）為7.9%。這一成長主要歸因於癌症和心血管疾病發病率的上升、核醫學基礎設施的擴建、對功能性影像技術需求的增加、放射性藥物研發的進步以及影像中心的擴張。

用於單光子發射電腦斷層掃描 (SPECT) 或正子斷層掃描 (PET) 的放射性藥物市場規模預計將在未來幾年強勁成長。預計到 2030 年，該市場規模將達到 96.2 億美元，複合年成長率 (CAGR) 為 8.1%。預測期內的成長預計將受到以下因素的驅動：對個人化診斷解決方案的需求不斷成長、治療診斷學（整合治療和診斷醫學）應用範圍的擴大、核醫學研究投入的增加、放射性同位素製造技術的進步以及 PET 成像在臨床應用中的日益普及。預測期內的關鍵趨勢包括：靶向放射性藥物在疾病特異性成像中的應用日益廣泛；對結合 SPECT 和 PET 模式的混合成像技術的需求不斷成長；為提高安全性和成像精度而更多地使用短半衰期同位素；放射性藥物在腫瘤學和神經病學領域的應用不斷擴大；以及對疾病早期檢測和功能成像的日益重視。

癌症發生率的上升預計將推動用於單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）的放射性藥物市場擴張。癌症是指體內異常細胞不受控制地生長和擴散，最終形成腫瘤並損害正常生理功能的一系列疾病。隨著人口老化，癌症發生率也在上升。這是因為老年人更容易累積基因突變，導致細胞不受控制地增殖。用於SPECT和PET的放射性藥物能夠以高靈敏度和高精度顯示腫瘤，從而支持癌症的早期檢測、準確分期、治療效果監測以及個人化醫療決策。例如，截至 2024 年 2 月，總部位於瑞士的國際組織世界衛生組織 (WHO) 預測，到 2050 年，新增癌症病例將超過 3,500 萬例，比 2022 年估計的 2,000 萬例增加 77%。因此，癌症盛行率的上升正在推動用於單光子發射電腦斷層掃描 (SPECT) 和正子斷層掃描 (PET) 的放射性藥物市場的成長。

正子斷層掃描（PET）放射性藥物市場的領導者正致力於開發創新產品，例如心臟正子斷層掃描（PET）示蹤劑，以提高冠狀動脈疾病影像診斷的準確性和可及性。心臟正子斷層掃描（PET）追蹤劑是一種放射性藥物，用於在PET成像中顯示血流並檢測心肌灌注減少的區域，從而幫助臨床醫生以非侵入性且高靈敏度的方式準確診斷冠狀動脈疾病並評估心肌缺血和心肌梗塞。例如，2024年9月，總部位於美國的醫療技術和藥物診斷公司GE醫療集團的心臟PET示蹤劑「Flyrcado（氟吡達唑F 18）」獲得美國食品藥物管理局（FDA）批准，用於已知或疑似冠狀動脈疾病患者的心肌灌注顯像（MPI）。 Flyrcado 是一種即用型單劑量放射性追蹤劑，半衰期長達 109 分鐘，可在同一檢查中進行高解析度 PET 成像、運動負荷試驗和重複掃描，與傳統的 SPECT MPI 顯影劑相比，顯著提高了診斷準確性。此次獲準擴大了先進心臟 PET 影像的適用範圍，使影像難度較高的患者受益，尤其是女性和高體重指數 (BMI) 患者。

目錄

第1章執行摘要

第2章 市場特徵

• 市場定義和範圍
• 市場區隔
• 主要產品和服務概述
• 全球單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場：吸引力評分及分析
• 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

• 供應鏈與生態系概述
• 清單：主要原料、資源和供應商
• 主要經銷商和通路合作夥伴名單
• 主要最終用戶列表

第4章：全球市場趨勢與策略

• 關鍵科技與未來趨勢
  • 生物技術、基因組學和精準醫療
  • 人工智慧和自主智慧
  • 數位化、雲端運算、巨量資料、網路安全
  • 永續性、氣候技術、循環經濟
  • 物聯網、智慧基礎設施、互聯生態系統
• 主要趨勢
  • 擴大靶向放射性藥物在疾病特異性成像的應用。
  • 對結合 SPECT 和 PET 兩種影像方式的混合影像診斷技術的需求日益成長。
  • 擴大短半衰期同位素的使用範圍，以提高診斷成像的安全性和準確性。
  • 放射性藥物在腫瘤學和神經病學中的應用日益廣泛
  • 人們對疾病早期檢測和功能成像越來越感興趣。

第5章 終端用戶產業市場分析

• 醫院
• 診斷影像中心
• 研究機構
• 核子醫學中心
• 其他最終用戶

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

• 全球單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場：PESTEL分析
• 全球單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場：規模、比較和成長率分析
• 全球單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場表現：規模和成長，2020-2025年
• 全球單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場預測：規模和成長，2025-2030年，2035年

第8章：全球市場總規模（TAM）

第9章 市場細分

• 按放射性藥物類型
• 單光子發射斷層掃描，正子斷層掃描
• 按放射性同位素類型
• Technetium-99m、氟-18、碘-123、鎵-68
• 透過行政途徑
• 注射、吸入劑、口服劑
• 按應用程式字段
• 腫瘤學、循環系統、神經病學及其他應用領域
• 最終用戶
• 醫院、診斷影像中心、研究機構和其他最終用戶
• 按類型細分：單光子發射電腦斷層掃描
• 心臟造影劑、骨骼造影劑、腎臟造影劑、肺部造影劑、甲狀腺造影劑
• 按類型細分：正子斷層掃描
• 用於造影、造影、循環系統造影、感染疾病/發炎性造影和造影疾病的造影劑。

第10章 區域與國別分析

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

• 單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場：競爭格局與市場佔有率，2024年
• 單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場：公司估價矩陣
• 單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場：公司概況
  • Cardinal Health Inc.
  • Bayer AG
  • Siemens Healthineers AG
  • GE HealthCare Technologies Inc.
  • Bracco Imaging SpA

第37章 其他大型企業和創新企業

• Lantheus Holdings Inc., Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications SA, Nordion Inc., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, EczacIbasI-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company

第38章：全球市場競爭基準分析與儀錶板

第39章：預計進入市場的新創企業

第40章 重大併購

第41章 具有高市場潛力的國家、細分市場與策略

• 單光子發射電腦斷層掃描 (SPECT) 或正子斷層掃描 (PET) 放射性藥物市場，2030 年：提供新機會的國家
• 單光子發射電腦斷層掃描（SPECT）或正子斷層掃描（PET）放射性藥物市場，2030年：提供新機會的細分市場
• 單光子發射電腦斷層掃描 (SPECT) 或正子斷層掃描 (PET) 放射性藥物市場，2030 年：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第42章附錄

SPECT or PET radiopharmaceuticals are radioactive substances administered to patients that emit detectable signals, enabling imaging of physiological functions and organ activity through SPECT or PET scanning systems. These compounds release signals captured by scanners, allowing detailed evaluation of biological processes for diagnostic purposes.

The primary types of radiopharmaceuticals of single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical include single photon emission computed tomography and positron emission tomography. Single photon emission computed tomography refers to imaging agents that emit gamma rays used for diagnostic imaging of organ function and structure. These radiopharmaceuticals utilize radioisotope types such as technetium-99m, fluorine-18, iodine-123, and gallium-68, and are administered through injectable, inhalation, and oral routes. The various applications involved are oncology, cardiology, neurology, and other application areas, and they are used by several end users such as hospitals, diagnostic imaging centers, research institutions, and other end users.

Tariffs are affecting the SPECT and PET radiopharmaceuticals market by increasing the cost of radioisotopes, specialized production equipment, and transportation logistics, which ultimately leads to higher overall diagnostic and treatment expenses. Segments such as positron emission tomography and technetium-99m-based radiopharmaceuticals are especially impacted due to their dependence on global supply chains and time-sensitive distribution requirements. Regions including North America and Europe are experiencing rising cost pressures, while Asia-Pacific is facing disruptions in isotope availability within the supply chain. However, tariffs are also encouraging local production of radioisotopes and stimulating investment in domestic nuclear medicine infrastructure, thereby improving long-term supply security and reducing reliance on imports.

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market research report is one of a series of new reports from The Business Research Company that provides single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market statistics, including single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry global market size, regional shares, competitors with a single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market share, detailed single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market segments, market trends and opportunities, and any further data you may need to thrive in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry. This single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market size has grown strongly in recent years. It will grow from $6.53 billion in 2025 to $7.04 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising prevalence of cancer and cardiovascular diseases, growth in nuclear medicine infrastructure, increasing demand for functional imaging techniques, advancements in radiopharmaceutical development, expansion of diagnostic imaging centers.

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market size is expected to see strong growth in the next few years. It will grow to $9.62 billion by 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized diagnostic solutions, growth in theranostics applications, rising investment in nuclear medicine research, advancements in radioisotope production technologies, expanding use of pet imaging in clinical practice. Major trends in the forecast period include increasing adoption of targeted radiopharmaceuticals for disease-specific imaging, growing demand for hybrid imaging techniques combining spect and pet modalities, rising use of short half-life isotopes for improved safety and imaging precision, expansion of radiopharmaceutical applications in oncology and neurology, increasing focus on early disease detection and functional imaging.

The increasing prevalence of cancer is anticipated to drive the expansion of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market going forward. Cancer refers to a group of diseases defined by the uncontrolled proliferation and spread of abnormal cells within the body, which can develop into tumors and disrupt normal physiological functions. The incidence of cancer is rising due to an aging population, as elderly individuals are more likely to accumulate genetic mutations that may lead to uncontrolled cell growth. SPECT and PET radiopharmaceuticals allow highly sensitive and accurate visualization of tumors, enabling early cancer detection, precise staging, monitoring of treatment response, and support for personalized therapy decisions. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are projected in 2050, representing a 77% rise compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is fueling the growth of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market.

Leading companies operating in the positron emission tomography (PET) radiopharmaceutical market are focusing on developing innovative products such as cardiac positron emission tomography (PET) tracers to improve diagnostic accuracy and accessibility in coronary artery disease imaging. Cardiac positron emission tomography (PET) tracers are radioactive compounds used in PET imaging to visualize blood flow and detect areas of reduced perfusion in the heart, helping clinicians accurately diagnose coronary artery disease and assess myocardial ischemia and infarction in a noninvasive and highly sensitive manner. For example, in September 2024, GE HealthCare, a U. S. -based medical technology and pharmaceutical diagnostics company, received U. S. Food and Drug Administration (FDA) approval for Flyrcado (flurpiridaz F 18), a cardiac PET (positron emission tomography) tracer for myocardial perfusion imaging (MPI) in patients with known or suspected coronary artery disease. Flyrcado is a ready-to-use unit dose radiotracer with a long half-life of 109 minutes, enabling high-resolution PET imaging, exercise stress testing, and rescans in the same session, improving diagnostic accuracy compared to traditional SPECT MPI agents. This approval expands access to advanced cardiac PET imaging, particularly benefiting difficult-to-image patients such as women and those with high body mass index (BMI).

In January 2026, SHINE Technologies LLC, a US-based healthcare technology and nuclear medicine production company, acquired the SPECT business of Lantheus Holdings for an undisclosed amount. With this acquisition, SHINE intends to enhance its capabilities and strengthen its market presence in nuclear medicine by taking over established SPECT diagnostic products and manufacturing operations while maintaining continuity and supporting the continued growth of the business. Lantheus Holdings Inc. is a US-based healthcare technology company that specialized in offering SPECT radiopharmaceutical diagnostic agents and related manufacturing operations used in single photon emission computed tomography imaging.

Major companies operating in the single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market are Cardinal Health Inc. , Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies Inc. , Bracco Imaging S. p. A. , Lantheus Holdings Inc. , Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc. , Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications S. A. , Nordion Inc. , NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, EczacIbasI-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company

North America was the dominating region in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market consists of sales of products such as diagnostic radiotracers, therapeutic radiopharmaceuticals, and radionuclide compounds such as technetium-99m, fluorine-18, and iodine-131. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type Of Radiopharmaceuticals: Single Photon Emission Computed Tomography; Positron Emission Tomography
• 2) By Radioisotope Type: Technetium-99m; Fluorine-18; Iodine-123; Gallium-68
• 3) By Route Of Administration: Injectable; Inhalation; Oral
• 4) By Application Areas: Oncology; Cardiology; Neurology; Other Application Areas
• 5) By End User: Hospitals; Diagnostic Imaging Centers; Research Institutions; Other End Users
• Subsegments:
• 1) By Single Photon Emission Computed Tomography: Cardiac Imaging Agents; Bone Imaging Agents; Renal Imaging Agents; Pulmonary Imaging Agents; Thyroid Imaging Agents
• 2) By Positron Emission Tomography: Oncology Imaging Agents; Neurology Imaging Agents; Cardiology Imaging Agents; Infection And Inflammation Imaging Agents; Metabolic Imaging Agents
• Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies Inc.; Bracco Imaging S.p.A.; Lantheus Holdings Inc.; Jubilant Pharmova Limited; Curium Pharma; Sofie Biosciences Inc.; Telix Pharmaceuticals Limited; Eckert & Ziegler SE; Advanced Accelerator Applications S.A.; Nordion Inc.; NorthStar Medical Radioisotopes LLC; ITM Isotope Technologies Munich SE; EczacIbasI-Monrol Nuclear Products; Radioisotope Centre POLATOM; IBA Radiopharma Solutions; Dongcheng; Pars Isotope Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Targeted Radiopharmaceuticals For Disease-Specific Imaging
  • 4.2.2 Growing Demand For Hybrid Imaging Techniques Combining Spect And Pet Modalities
  • 4.2.3 Rising Use Of Short Half-Life Isotopes For Improved Safety And Imaging Precision
  • 4.2.4 Expansion Of Radiopharmaceutical Applications In Oncology And Neurology
  • 4.2.5 Increasing Focus On Early Disease Detection And Functional Imaging

5. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diagnostic Imaging Centers
• 5.3 Research Institutions
• 5.4 Nuclear Medicine Centers
• 5.5 Other End Users

6. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Segmentation

• 9.1. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single Photon Emission Computed Tomography, Positron Emission Tomography
• 9.2. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Radioisotope Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Technetium-99m, Fluorine-18, Iodine-123, Gallium-68
• 9.3. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Injectable, Inhalation, Oral
• 9.4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Application Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Cardiology, Neurology, Other Application Areas
• 9.5. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Diagnostic Imaging Centers, Research Institutions, Other End Users
• 9.6. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Sub-Segmentation Of Single Photon Emission Computed Tomography, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cardiac Imaging Agents, Bone Imaging Agents, Renal Imaging Agents, Pulmonary Imaging Agents, Thyroid Imaging Agents
• 9.7. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Sub-Segmentation Of Positron Emission Tomography, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology Imaging Agents, Neurology Imaging Agents, Cardiology Imaging Agents, Infection And Inflammation Imaging Agents, Metabolic Imaging Agents

10. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Regional And Country Analysis

• 10.1. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 11.1. Asia-Pacific Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 12.1. China Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 13.1. India Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 14.1. Japan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 15.1. Australia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 16.1. Indonesia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 17.1. South Korea Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 18.1. Taiwan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 19.1. South East Asia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 20.1. Western Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 21.1. UK Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 22.1. Germany Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 23.1. France Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 24.1. Italy Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 25.1. Spain Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 26.1. Eastern Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 27.1. Russia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 28.1. North America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 29.1. USA Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 30.1. Canada Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 31.1. South America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 32.1. Brazil Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 33.1. Middle East Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

• 34.1. Africa Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Regulatory and Investment Landscape

36. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Competitive Landscape And Company Profiles

• 36.1. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Company Profiles
  • 36.3.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GE HealthCare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bracco Imaging S.p.A. Overview, Products and Services, Strategy and Financial Analysis

37. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Other Major And Innovative Companies

• Lantheus Holdings Inc., Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications S.A., Nordion Inc., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, EczacIbasI-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company

38. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

41. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market High Potential Countries, Segments and Strategies

• 41.1 Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer